Search Results
Your search for ,HIS matches 4425 pages
Showing 3901 - 3950HIV-Related Lymphoma Can Be Safely Treated With Transplant
Human immunodeficiency virus (HIV)-positive patients with relapsed/refractory lymphoma can safely undergo autologous hematopoietic cell transplantation, according to results of a phase II multicenter trial presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition in...
Targeting Biliary Tract Cancers Through Genomic Profiling
Biliary tract cancers are challenging, but a large genomic profiling study has identified potentially clinically relevant genomic alterations in up to two-thirds of patients.1 “The diverse landscape of clinically relevant genomic alterations in biliary tract cancers can serve as targets for...
Expert Point of View: Jaffer A. Ajani, MD
Jaffer A. Ajani, MD, Professor of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center, Houston, discussed the two studies. He emphasized the impressive cytoreductive activity of AMG 337. “Granted, it was only 13 patients, but in 13 patients, 8 [responders] is a...
Inhibiting the MET Pathway in Gastroesophageal Cancer: Hits and Misses
The MET pathway appears to be important in gastroesophageal cancers, but response to a targeted agent may depend on the class of drugs. A robust response to the novel small-molecule MET inhibitor AMG 337 was observed, but a monoclonal antibody targeting MET fell flat, in studies reported at the...
Addressing the Global Cancer Burden
Since 1990, the annual global death toll from cancer has risen about 40%, and that number is projected to increase from the current level of approximately 8 million cancer deaths per year to more than 13 million by 2030. The poorer, resource-challenged regions of the world will suffer a...
Big Data and the Promise of Precision Medicine in Cancer
Precision medicine—and its promise to revolutionize how we understand disease and care for our patients—is a concept that oncology has understood and embraced for well over a decade. But millions of Americans recently heard about the concept for the first time when President Obama announced a...
Active Surveillance in Intermediate-Risk Prostate Cancer Called Into Question
A study presented at the 2015 Genitourinary Cancers Symposium calls into question the use of active surveillance in patients with intermediate-risk prostate cancer. Patients with intermediate-risk prostate cancer managed with active surveillance had almost a four times higher risk of prostate...
Caregivers May Want to Know About a Patient’s Impending Death but May Be Afraid to Ask
The likelihood of impending death of patients with advanced cancer “is one of those questions that many people want to know about, but they are too afraid to ask,” David Hui, MD, MSc, said in an interview with The ASCO Post. Dr. Hui is lead author of a study, published in Cancer, on clinical signs...
Recognizing Physical Signs Associated With Impending Death Can Assist Clinicians, Patients, and Caregivers With Complex Decisions
In a recently published study of patients with advanced cancer whose status was systematically documented twice a day, from the time of admission to a palliative care unit until death or discharge, investigators identified eight physical signs associated with death within 3 days. Taken together...
The Center of Who We Are
The following essay by Eric M. Genden, MD, is adapted from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories, which was coedited by Stan Winokur, MD, and Vincent Coppola and published in May 2014. The book is available on Amazon.com and thebigcasino.org. There’s...
ASCO Commends Dr. Varmus for Outstanding Leadership
Following news of Dr. Varmus’ planned departure from the National Cancer Institute (NCI), ASCO issued the following statement: ASCO is enormously grateful for the service and leadership of Harold Varmus, MD, as Director of the National Cancer Institute [NCI]. During Dr. Varmus’ tenure, the...
Harold Varmus, MD, Steps Down as NCI Director, Douglas Lowy, MD, Named Acting Director
Harold Varmus, MD, who has led the National Cancer Institute (NCI) at the National Institutes of Health (NIH) for nearly 5 years, has announced that he will step down from his post, effective March 31, 2015. “It has been our great fortune to have Dr. Varmus at the helm of the NCI,” said NIH...
Dr. Halsted’s Breast Amputation Specimens, Johns Hopkins Hospital, 1894
A Century of Progress The text and photographs on these pages represent the establishment of oncology as a viable medical specialty during the late 1800s and showcase the early medical advances and treatments in cancer. The images and captions are excerpted from a four-volume series of books titled ...
Herbal Supplements: Increasing Problems
In Don Quixote, the 1605 Spanish literary masterpiece by Miguel Cervantes, “Balsam of Fierabras” is mentioned often as a therapeutic panacea. It calls for mixing rosemary, wine, oil, and salt. As the story goes, the knight relied heavily on this herbal preparation to relieve him of pain from the...
Medicine Turned Upside Down
BookmarkTitle: The Patient Will See You Now: The Future of Medicine Is in Your HandsAuthor: Eric Topol, MDPublisher: Basic BooksPublication date: January 2015Price: $28.99; hardcover, 384 pagesMost books about health care center on fixing broken parts of the massive $3 trillion system, as seen with ...
Seattle Children’s Names Jeff Sperring, MD, New Chief Executive Officer
Seattle Children’s Hospital announced that the Board of Trustees has named Jeff Sperring, MD, Chief Executive Officer, effective early in May. Dr. Sperring, who currently serves as President and Chief Executive Officer of Riley Hospital for Children at Indiana University Health, will continue to...
Beating the Odds in The Big Casino
More than 35 ASCO members contributed personal essays to a recently published collection of stories about humanism in medicine, including ASCO Past Presidents Paul A. Bunn, Jr, MD, FASCO, and Emil J. Freireich, MD, FASCO, and current President-Elect Julie M. Vose, MD, MBA, FASCO. The Big Casino:...
FDA Names Geoffrey Kim, MD, Director of the Division of Oncology Products
The U.S. Food and Drug Administration (FDA) recently announced the appointment of Geoffrey Kim, MD, as Director of the Division of Oncology Products 1 (DOP1) in the Office of Hematology Oncology Products. Dr. Kim assumed this position effective March 22, 2015. Dr. Kim previously served as the...
Ongoing Controversies in Allocating Our Health‑Care Resources
Disparities of care that result in poorer outcomes among certain populations have long been an issue addressed by the cancer community and its major organizations such as ASCO. While ethnicity and race play key roles in this ongoing debate over equitable allocation of our precious health-care...
Optimal Timing of Rectal Surgery: 60 Days or Less Post Chemoradiation Therapy
For the treatment of locally advanced rectal cancer, the optimal timing between the end of neoadjuvant chemoradiation therapy and surgical resection appears to be 60 days, according to an analysis of the National Cancer Database presented at the 2015 Gastrointestinal Cancers Symposium.1 An interval ...
Remembering Neurosurgeon and Writer Paul Kalanithi, MD
What initially drew me to read the eloquent essay by Paul Kalanithi, MD, in The New York Times—“How Long Have I Got Left?”—was its provocative title.1 What kept me there was the moving description of his quick transition from healthy physician with a brilliant career in neurosurgery to terminally...
Association of Community Cancer Centers Names Steven L. D’Amato, BSPharm, BCOP, President
Steven L. D’Amato, BSPharm, BCOP, became President of the Association of Community Cancer Centers (ACCC) at its 41st Annual Meeting on March 18, 2015, in Arlington, Virginia. He is Executive Director of New England Cancer Specialists and a Clinical Associate Professor at the University of Tufts...
I Refuse to Capitulate to Cancer
Editor’s note: We regret to announce that Paul Kalanithi, MD, passed away on March 9, 2015. Dr. Kalanithi was Chief Resident in Neurological Surgery at Stanford University when he shared his story, reprinted here, with The ASCO Post just over 1 year ago, in March 2014. We extend our deepest...
Colorectal Cancer Is Significantly Increasing Among Younger Adults and Being Diagnosed at Later Stages
A growing body of literature indicates that the incidence of colorectal cancer is rising among people under age 50, according to Jason A. Zell, DO, MPH. Dr. Zell is the corresponding author of one of the two recent studies finding significant increases in colorectal cancer among adults aged 20 to...
Shining a Spotlight on Epithelioid Hemangioendothelioma
In the winter of 2013, my son, Dmitriy, now 26, had a cough that wouldn’t go away. After several rounds of antibiotics failed to halt the persistent problem, a pulmonologist we consulted ordered a chest x-ray, which showed a large tumor lodged between Dmitriy’s lungs. Although the doctor said the...
A Surgeon Cuts to the Chase
BookmarkTitle: The Cost of Cutting: A Surgeon Reveals the Truth Behind a Multibillion-Dollar IndustryAuthor: Paul A. Ruggieri, MDPublisher: Berkley BooksPublication date: September 2014Price: $16.00; paperback, 320 pages The woman seated on the exam table was lean and fit and seemed perfectly at...
Technology’s Double-Edged Sword: One Woman’s Story
Bookmark Title: Pandora’s DNA: Tracing the Breast Cancer Genes Through History, Science, and One Family TreeAuthor: Lizzie StarkPublisher: Chicago Review PressPublication date: October 2014Price: $26.95; hardcover, 336 pages If we wish to learn more about cancer, we must concentrate on the cellular ...
Adding Cetuximab to First-Line FOLFIRI Does Not Benefit Metastatic Colorectal Cancer Patients With RAS Mutations
The phase III CRYSTAL trial showed that the addition of cetuximab (Erbitux) to first-line FOLFIRI (fluorouracil, leucovorin, and irinotecan) significantly improved overall survival, progression-free survival, and objective response rates in patients with KRAS codon 12/13 (exon 2) wild-type...
Why Just Having ‘Good’ Communication Skills Is Not Enough for Talking With Seriously Ill Patients
In the Institute of Medicine’s 2014 report Dying in America,1 the report’s authors found that while frequent clinician-patient conversations about end-of-life care, goals, and preferences are necessary to avoid unwanted treatment, most patients do not have those conversations with their physicians. ...
St. Jude Children’s Research Hospital Appoints Chair of Department of Radiation Oncology
St. Jude Children’s Research Hospital has named Thomas E. Merchant, DO, PhD, as Chair of the Department of Radiation Oncology. Dr. Merchant will hold the Baddia J. Rashid Endowed Chair in Radiation Oncology. “Dr. Merchant is a proven leader in pediatric radiotherapy and will be instrumental in...
Jim Hu, MD, Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College
Jim Hu, MD, has been appointed Director of the LeFrak Center for Robotic Surgery at NewYork-Presbyterian/Weill Cornell Medical Center and recruited as the Ronald Lynch Chair of Urologic Oncology at Weill Cornell Medical College. He assumed his new role on February 1. Dr. Hu is an expert in the use...
James P. Allison, PhD, Wins 2015 Paul Ehrlich and Ludwig Darmstaedter Prize
James P. Allison, PhD, Chair of Immunology at The University of Texas MD Anderson Cancer Center, has received the 2015 Paul Ehrlich and Ludwig Darmstaedter Prize in recognition of his work in the field of immunotherapy. “In immunotherapy, it’s not the tumor but the immune system that is targeted....
Evidence Mounts for Clinical Utility of AR-V7 in Treatment Selection for Advanced Prostate Cancer
The search is on in prostate cancer to identify predictive and prognostic biologic and genomic markers that go beyond traditional ones. Several groups are working in this area. One marker that has received much attention is a splice abnormality in the androgen receptor (AR) called AR-V7. Two...
2015 Canada Gairdner Awards Honor Top Medical Researchers Worldwide
The Gairdner Foundation named the winners of the 2015 Canada Gairdner Awards, recognizing some of the most significant medical discoveries around the world. The awards provide a $100,000 (CAD) prize to each scientist for his or her work. The aim of the Gairdner Awards is to promote a culture of...
AACR Honors Cancer Pioneers at the 2015 Annual Meeting
The American Association for Cancer Research (AACR) recognized six oncologists making valuable contributions to their fields with awards at the Association’s Annual Meeting 2015, held in Philadelphia from April 18–22. William C. Hahn, MD, PhD, was awarded with the 39th Annual AACR–Richard and Hinda ...
Lewis C. Cantley, PhD, Honored With AACR Memorial Lectureship
The American Association for Cancer Research (AACR) honored Lewis C. Cantley, PhD, with the 9th Annual Princess Takamatsu Memorial Lectureship at the AACR Annual Meeting 2015. Dr. Cantley is the Meyer Director of the Sandra and Edward Meyer Cancer Center, the Margaret and Herman Sokol Professor in...
Dana-Farber President and CEO Edward J. Benz, Jr, MD, to Retire in 2016
Dana-Farber President and CEO Edward J. Benz, Jr, MD, has announced he will retire from the Dana-Farber Cancer Institute (DFCI) in 2016, after 16 years running the organization. Dr. Benz will also vacate the positions as Director and Principal Investigator of the Dana-Farber/Harvard Cancer Center...
Richard Gilbertson, MD, PhD, Leaves St. Jude Children’s Research Hospital
St. Jude Children’s Research Hospital announced the departure of Scientific and Comprehensive Cancer Center Director, Richard Gilbertson, MD, PhD. Dr. Gilbertson will be Director of the Cambridge Cancer Centre at the University of Cambridge. Since joining St. Jude in 2000, Dr. Gilbertson has led...
Owen N. Witte, MD, Recognized With AACR G.H.A. Clowes Memorial Award
The American Association for Cancer Research (AACR) honored Owen N. Witte, MD, Founding Director of the Eli & Edythe Broad Center of Regenerative Medicine & Stem Cell Research, and Distinguished Professor of Microbiology, Immunology, and Molecular Genetics at the University of California,...
Cancer Control in Primary Care Courses Offered in India
ASCO International’s mission is to optimize care for every patient with cancer in the world. To achieve that goal, it is critical to establish collaborations in all sectors of the health-care system. ASCO International’s newest course, Cancer Control in Primary Care, helps to address this need by...
Evidence of Recurrence-Free, Disease-Free, and Overall Survival Benefit of Aspirin and COX‑2 Inhibitor Use in Stage III Colon Cancer
In an analysis from the Cancer and Leukemia Group B (CALGB) 89803 adjuvant trial reported in the Journal of the National Cancer Institute, Kimmie Ng, MD, MPH, of Dana-Farber Cancer Institute, Boston, and colleagues found consistent trends suggesting benefit of aspirin use and cyclo-oxygenase-2...
Richard Pazdur, MD, and Anthony S. Fauci, MD, Included in Fortune’s List of the World’s 50 Greatest Leaders
Richard Pazdur, MD, Director of the Office of Oncology and Hematology Products at the U.S. Food and Drug Administration (FDA) was named one of the world’s 50 greatest leaders by Fortune Magazine. The list also included names such as Pope Francis, Apple CEO Tim Cook, Chief Justice of the United...
Overweight Girls Face Increased Risk of Colorectal Cancer Later in Life
Girls who are overweight as young children and teens may face increased risk for colorectal cancer decades later, regardless of what they weigh as adults, suggests a new study published by Xuehong Zhang, MD, ScD, Instructor at Harvard Medical School, and colleagues in Cancer Epidemiology,...
Should We Be Worried If Patients Tolerate Endocrine Therapy Well?
When meeting with patients to discuss adjuvant endocrine therapy for breast cancer, the question often arises, “How will I know that the treatment is working?” While the efficacy of these treatments has been demonstrated for the majority of patients in multiple large randomized clinical trials,...
Heal Thy Patient … Reflections on the Human Side of Medicine
Dr. Are extended to me the opportunity to make additional comments about his article. I am the husband of the most wonderful Mrs. X he discusses. As always, Dr. Are’s comments are very kind and generous. Three Roles Based on my experience and observations, I would like to mention three roles a...
Heal Thy Patient … Reflections on the Human Side of Medicine
The first time I met Mrs. X and her husband was to discuss the surgical treatment options for pancreatic cancer. She had just been diagnosed with pancreatic cancer at her local hospital and was being referred to a tertiary care center for operative management. Mrs. X and her husband were no...
Cancer Has Left an Indelible Mark on Me
Even though today I’m cancer-free, the experience of getting a cancer diagnosis and going through treatment leaves an indelible mark on your psyche—as well as your body—that time doesn’t erase. Once you have cancer, you become a cancer survivor, and that status doesn’t change. I’ve known many...
Robert Coleman, MD, Begins SGO and Foundation Presidency
Robert L. Coleman, MD, Professor, Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, started his 1-year term as the 47th President of the Society of Gynecologic Oncology (SGO) and 5th President of the Foundation for Gynecologic...
Bombarded With Changes in Health Care and Beyond, Gynecologic Oncologists Prepare for the Challenges Ahead
Physicians are being “bombarded” with changes in health care and beyond, Richard R. Barakat, MD, FACS, noted in his Presidential Address at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer. These changes are being precipitated by steeply rising health-care costs amid...
Researchers Discuss Pilot Study on Hallucinogenic Therapies for Cancer Anxiety
Although varying levels of existential distress are near-ubiquitous among patients with cancer, evidence-based interventions in this clinical area remain somewhat elusive. Seeking to explore novel approaches in the palliative care environment, New York University (NYU) School of Medicine principal...
